Mymetics Corporation
MYMX
Other OTC0.00
USD
- -
- -
CIK
0000927761
ISIN
US62856A3005
CUSIP
62856A300
Return %
Stock
S&P500
1Y
0.00
19.01
3Y
-100.00
65.48
5Y
-100.00
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ronald Kempers
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- ROUTE DE LA CORNICHE 4 Epalinges VD Switzerland 1066
- IPO Date
- Oct 26, 1999
- CIK
- 0000927761
- Website
- mymetics.com
- Similar Companies
- Business
- Mymetics Corporation engages in the research and development of vaccines for infectious and life-disabling diseases, headquartered in Epalinges, Switzerland, and founded in 1990. The company specializes in virosome-based vaccine technology, utilizing lipid-based carriers that combine viral proteins and rationally designed antigens to induce protective mucosal immune responses. Mymetics' core product pipeline includes vaccine candidates targeting HIV-1/AIDS, Covid-19, intranasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya. It operates internationally with research activities notably in Switzerland and the Netherlands. Mymetics has established significant collaborations and strategic partnerships including agreements with the Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases, focusing on virosome-based malaria transmission-blocking vaccines. Additionally, the company collaborates with Sanofi Pasteur Biologics to evaluate the immunogenicity of influenza vaccines and has research engagements with MedImmune on RSV vaccines. Recently, Mymetics has progressed its Covid-19 vaccine development based on its virosome platform and maintains active joint research projects such as one with eTheRNA Immunotherapy on cancer immunotherapy. In the last two years, Mymetics has focused on advancing preclinical and clinical trials of its vaccine candidates, including early-stage HIV vaccine trials in Belgium and malaria vaccines in Tanzania. The company continues to expand its virosome vaccine portfolio and enhance its research capabilities, reflecting a strategic emphasis on innovative preventative vaccines for infectious diseases through cutting-edge virosome technology. Mymetics Corporation was formerly known as ICHOR Corporation before its name change in 2001 and remains headquartered in Switzerland with subsidiaries that support its R&D operations internationally.